Biotech · Private company · Monmouth Junction, NJ, US
Taxis Pharmaceuticals, Inc.
Track this companyFree. Adds Taxis Pharmaceuticals, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials0None registered
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
NIH awards6
- Lead identification of oral FtsZ inhibitors for the treatment of Clostridioides difficile infections(CDI)Fiscal year 2026 · $294.7KNIH RePORTER 1R43AI197297-01 · fetched Nov 12, 2026
- Lead optimization of a novel cyclic aryl-indole efflux pump inhibitor (EPI) series in combination with levofloxacin against Pseudomonas aeruginosaFiscal year 2026 · $875.8KNIH RePORTER 5R44AI174351-03 · fetched Nov 12, 2026
- Lead optimization of oral DHFR inhibitor for the treatment of multidrug-resistant N. gonorrhoeae infections.Fiscal year 2026 · $1MNIH RePORTER 5R44AI191886-02 · fetched Nov 12, 2026
- Lead optimization of oral DHFR inhibitor for the treatment of multidrug-resistant N. gonorrhoeae infections.Fiscal year 2025 · $1MNIH RePORTER 1R44AI191886-01 · fetched Nov 12, 2026
- Lead optimization of a novel cyclic aryl-indole efflux pump inhibitor (EPI) series in combination with levofloxacin against Pseudomonas aeruginosaFiscal year 2025 · $889.6KNIH RePORTER 5R44AI174351-02 · fetched Nov 12, 2026
- Lead optimization of a novel cyclic aryl-indole efflux pump inhibitor (EPI) series in combination with levofloxacin against Pseudomonas aeruginosaFiscal year 2024 · $910.2KNIH RePORTER 1R44AI174351-01A1 · fetched Nov 12, 2026